Funding
← Back to your selection

British Business Bank

Activity from announced rounds

Activity in this selectionBiotech

British Business Bank is the UK’s economic development bank, supporting business access to finance through investment programmes, funds and financing partners.

Its Future Fund: Breakthrough programme, delivered by British Patient Capital, co-invests with private investors in later-stage, R&D-intensive UK companies. It targets technologies such as quantum computing, cleantech and life sciences, where development requires substantial capital.

Applications to that programme come from a qualifying sponsor investor, rather than directly from the company. The published criteria require a round of at least £30 million, with the programme contributing no more than 30% on the sponsor investor’s terms.

Sources
Rounds participated in
6
Confirmed lead rounds
1
4 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$675M
5 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series B2
Series A1

By primary sector

Biotech6

By country

United Kingdom5
United States1

Rounds

6 in this selection
Microbiotica

Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment.

£36MSeries C first close
Lead
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Participant
IMU Biosciences

Profiles human immune systems using multi-omic analysis and machine learning for disease research.

$53MSeries A
Role not disclosed
Nuclera

Provides rapid access to functional proteins through benchtop eProtein Discovery System

$12MSeries C+
Role not disclosed